CalciMedica, Inc. Business Combination, Acquisition Related Costs
CalciMedica, Inc. (CALC) reported Business Combination, Acquisition Related Costs of $10.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2025-03-27
- CalciMedica, Inc. business combination, acquisition related costs for the quarter ending 2024-12-31 was $0.00.
- CalciMedica, Inc. business combination, acquisition related costs for the quarter ending 2024-09-30 was $0.00.
- CalciMedica, Inc. business combination, acquisition related costs for the quarter ending 2024-06-30 was $0.00.
- CalciMedica, Inc. business combination, acquisition related costs for the quarter ending 2024-03-31 was $10.50M, a 0.00% change year-over-year.
- CalciMedica, Inc. business combination, acquisition related costs for fiscal 2024 was $10.50M, a 0.00% change from fiscal 2023.
- CalciMedica, Inc. business combination, acquisition related costs for fiscal 2023 was $10.50M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $10.50M 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $10.50M 10-Q · filed 2024-11-13 | $10.50M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $10.50M 10-Q · filed 2024-08-12 | $10.50M derived: sum of 3 quarters · filed 2024-08-12 | $10.50M derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | $10.50M 10-Q · filed 2024-05-13 | $10.50M derived: sum of 2 quarters · filed 2024-05-13 | $10.50M derived: sum of 3 quarters · filed 2024-05-13 | $10.50M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $10.50M 10-K · filed 2024-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $10.50M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $10.50M 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | $10.50M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |